Susquehanna International Group, LLP Contrafect Corp Call Options Transaction History

Susquehanna International Group, LLP

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2022 Aug 15, 2022	SELL	$2.79 - $4.45 $6,417 - $10,235	-2,300 Reduced 1.55%	146,000 $448,000
Q1 2022 May 16, 2022	BUY	$2.26 - $3.84 $2,711 - $4,608	1,200 Added 0.82%	148,300 $541,000
Q4 2021 Feb 14, 2022	SELL	$2.47 - $4.14 $142,272 - $238,463	-57,600 Reduced 28.14%	147,100 $387,000
Q3 2021 Nov 15, 2021	SELL	$3.19 - $4.43 $55,187 - $76,639	-17,300 Reduced 7.79%	204,700 $829,000
Q2 2021 Aug 11, 2021	BUY	$3.58 - $4.9 $202,270 - $276,850	56,500 Added 34.14%	222,000 $977,000
Q1 2021 May 17, 2021	BUY	$4.46 - $6.68 $738,130 - $1.11 Million	165,500 New	165,500 $794,000

49.2K

Ticker CFRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,332,700
Market Cap $1.18M
Description
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.